Literature DB >> 10691797

Plasma from ESRD patients inhibits nitric oxide synthase activity in cultured human and bovine endothelial cells.

S Xiao1, R J Schmidt, C Baylis.   

Abstract

Our recent observations of reduced total nitric oxide synthesis in renal failure patients on peritoneal dialysis and haemodialysis suggest that hypertension in end-stage renal disease involves lack of vasodilatory endothelial NO. To directly test this, uraemic plasma was obtained from dialysis patients and incubated with cultured vascular endothelial cells, to determine the effect on nitric oxide synthase (NOS) activity in comparison with plasma from subjects with normal renal function. After incubation for 6 h with 20% uraemic plasma from peritoneal dialysis and immediately prehaemodialysis patients, NOS activity was reduced in human dermal microvascular endothelial cells. Haemodialysis did not remove the NOS-inhibitory activity of uraemic plasma nor did it activate inducible NOS, as NOS activity was always similar in control and dexamethasone pretreated cells. Nitric oxide production (accumulation of nitrite and nitrate) was lower in cells incubated with uraemic vs. normal plasma and excess arginine increased nitric oxide production by cells previously exposed to uraemic medium. This inhibitory effect was not associated with co-factor deficiency but did correlate with plasma concentrations of endogenous NOS inhibitors. These in vitro findings suggest that low endothelial NOS activity may contribute to hypertension in end stage renal disease patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691797      PMCID: PMC2745248          DOI: 10.1046/j.1365-201x.2000.00640.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  26 in total

1.  Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction.

Authors:  M F Hand; W G Haynes; D J Webb
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

2.  Acetate intolerance is mediated by enhanced synthesis of nitric oxide by endothelial cells.

Authors:  A Amore; P Cirina; S Mitola; L Peruzzi; R Bonaudo; B Gianoglio; R Coppo
Journal:  J Am Soc Nephrol       Date:  1997-09       Impact factor: 10.121

3.  Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients.

Authors:  B Anderstam; K Katzarski; J Bergström
Journal:  J Am Soc Nephrol       Date:  1997-09       Impact factor: 10.121

4.  S-nitrosohemoglobin in the fetal circulation may represent a cycle for blood pressure regulation.

Authors:  E F Funai; A Davidson; S P Seligman; T H Finlay
Journal:  Biochem Biophys Res Commun       Date:  1997-10-29       Impact factor: 3.575

5.  Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency.

Authors:  B Marescau; G Nagels; I Possemiers; M E De Broe; I Becaus; J M Billiouw; W Lornoy; P P De Deyn
Journal:  Metabolism       Date:  1997-09       Impact factor: 8.694

6.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

Authors:  J T Kielstein; R H Böger; S M Bode-Böger; J Schäffer; M Barbey; K M Koch; J C Frölich
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

7.  Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture.

Authors:  O Saijonmaa; K Metsärinne; F Fyhrquist
Journal:  Blood Press       Date:  1997-01       Impact factor: 2.835

Review 8.  Nitric oxide and blood pressure: effects of nitric oxide deficiency.

Authors:  C Baylis; P Vallance
Journal:  Curr Opin Nephrol Hypertens       Date:  1996-01       Impact factor: 2.894

9.  Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.

Authors:  X Zhang; F A Recchia; R Bernstein; X Xu; A Nasjletti; T H Hintze
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

Review 10.  Nitric oxide synthase gene polymorphism and its influence on cardiovascular disease.

Authors:  M Soma; T Nakayama; K Kanmatsuse
Journal:  Curr Opin Nephrol Hypertens       Date:  1999-01       Impact factor: 2.894

View more
  10 in total

1.  Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells.

Authors:  S Xiao; L Wagner; J Mahaney; C Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2001-06

2.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.

Authors:  Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

Review 3.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

4.  Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease.

Authors:  S Xiao; L Wagner; R J Schmidt; C Baylis
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

5.  Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease.

Authors:  Mehmet Kanbay; Mahmut Ilker Yilmaz; Alper Sonmez; Faruk Turgut; Mutlu Saglam; Erdinc Cakir; Mujdat Yenicesu; Adrian Covic; Diana Jalal; Richard J Johnson
Journal:  Am J Nephrol       Date:  2011-03-08       Impact factor: 3.754

6.  Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport.

Authors:  Laszlo Wagner; Janet D Klein; Jeff M Sands; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2002-09

7.  Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis.

Authors:  Yildiz Oner-Iyidogan; Pernur Oner; Hikmet Kocak; Figen Gurdol; Seldag Bekpinar; Yesim Unlucerci; Yasar Caliskan; Pinar Cetinalp-Demircan; Taner Kocak; Aydin Turkmen
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

8.  In vivo renal arginine release is impaired throughout development of chronic kidney disease.

Authors:  Gin-Fu Chen; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-11

9.  Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis.

Authors:  Laszlo Wagner; Amy Riggleman; Aaron Erdely; William Couser; Chris Baylis
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

10.  Autologous Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 Positive Cell Transplantation for Hemodialysis Patients with Critical Limb Ischemia: A Prospective Phase II Clinical Trial.

Authors:  Takayasu Ohtake; Yasuhiro Mochida; Kunihiro Ishioka; Machiko Oka; Kyoko Maesato; Hidekazu Moriya; Sumi Hidaka; Satoshi Higashide; Tetsuya Ioji; Yasuyuki Fujita; Atsuhiko Kawamoto; Masanori Fukushima; Shuzo Kobayashi
Journal:  Stem Cells Transl Med       Date:  2018-07-30       Impact factor: 6.940

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.